Ryan T. Anderson

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Stephen B. Keysar, David P. Astling, Ryan T. Anderson et al. · Molecular Oncology · 2013 · 164 citations · Full text

Medicine, Oncology, Pharmacology +16

Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

Stephen B. Keysar, Phuong N. Le, Ryan T. Anderson et al. · Cancer Research · 2013 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam et al. · Clinical Cancer Research · 2014 · 73 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Hedgehog Signaling Drives Radioresistance and Stroma-Driven Tumor Repopulation in Head and Neck Squamous Cancers

Gregory N. Gan, Justin R. Eagles, Stephen B. Keysar et al. · Cancer Research · 2014 · 68 citations · Full text

Medicine, Oncology, Radiation Oncology +14

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

Ryan T. Anderson, Stephen B. Keysar, Daniel W. Bowles et al. · Molecular Cancer Therapeutics · 2013 · 31 citations · Full text

Medicine, Oncology, Pharmacology +16